Heterogeneity of circulating immune complexes in chronic lung diseases. 1982

K M Cooper, and M Moore

Circulating immune complex (IC) levels in sera from 58 healthy controls and a total of 212 patients with various chronic lung diseases were measured using 3 assays. Two complement-dependent assays (C1q fluid phase and Raji) and a complement-independent assay (L1210) were employed. The 3 assays generally revealed similar patterns of reactivity when control and pathological groups were compared, with the L1210 assay invariably demonstrating the lowest incidence of positive values in each group. The most significant elevations in IC levels were exhibited in bronchiectasis and bronchogenic carcinoma. However, within these two groups correlations between IC assays performed on individual sera were poor. Significant but weak correlations (p less than 0.01) were only observed for C1q vs Raji in bronchiectasis and C1q vs L1210 in bronchogenic carcinoma. Complement-binding ICs were present to a similar extent in both conditions. However, non-complement binding ICs were found to be more common in bronchiectasis. The relative sensitivity of the tests and the contribution of interfering factors to the disparity between the assays is discussed. However, the interpretation favoured is that the lack of correlation is primarily a reflection of the intrinsic heterogeneity of immune complexes formed under similar and dissimilar pathological conditions.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011309 Preservation, Biological The process of protecting various samples of biological material. Biological Preservation,Preservation, Biologic,Biologic Preservation
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D001987 Bronchiectasis Persistent abnormal dilatation of the bronchi. Cylindrical Bronchiectasis,Cystic Bronchiectasis,Saccular Bronchiectasis,Varicose Bronchiectasis,Bronchiectases,Bronchiectasis, Cylindrical,Bronchiectasis, Cystic,Bronchiectasis, Saccular,Bronchiectasis, Varicose,Cylindrical Bronchiectases,Cystic Bronchiectases,Saccular Bronchiectases,Varicose Bronchiectases
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003166 Complement Activating Enzymes Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways. Activating Enzymes, Complement,Enzymes, Complement Activating

Related Publications

K M Cooper, and M Moore
April 1984, Gastroenterologie clinique et biologique,
K M Cooper, and M Moore
January 1981, Terapevticheskii arkhiv,
K M Cooper, and M Moore
January 1977, Lancet (London, England),
K M Cooper, and M Moore
January 1991, Romanian journal of internal medicine = Revue roumaine de medecine interne,
K M Cooper, and M Moore
January 1985, Sovetskaia meditsina,
K M Cooper, and M Moore
April 1982, Parassitologia,
K M Cooper, and M Moore
October 1981, Chest,
K M Cooper, and M Moore
January 1981, Die Medizinische Welt,
K M Cooper, and M Moore
April 1983, Journal of clinical & laboratory immunology,
Copied contents to your clipboard!